Shelton Capital Management trimmed its holdings in shares of Celgene Co. (NASDAQ:CELG) by 0.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,918 shares of the biopharmaceutical company’s stock after selling 540 shares during the quarter. Shelton Capital Management’s holdings in Celgene were worth $9,593,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in shares of Celgene by 4,290.5% in the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after purchasing an additional 8,217,433 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after purchasing an additional 3,084,227 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Celgene by 1,489.2% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after purchasing an additional 1,787,052 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after purchasing an additional 1,610,056 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Celgene by 11.5% in the 3rd quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock valued at $2,181,818,000 after purchasing an additional 1,546,673 shares during the last quarter. 78.67% of the stock is currently owned by hedge funds and other institutional investors.
Celgene Co. (NASDAQ CELG) opened at $89.61 on Friday. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99. Celgene Co. has a 1-year low of $86.55 and a 1-year high of $147.17. The firm has a market cap of $67,628.11, a price-to-earnings ratio of 25.03, a price-to-earnings-growth ratio of 0.63 and a beta of 1.58.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. During the same quarter in the prior year, the company posted $1.61 earnings per share. The business’s revenue was up 16.9% on a year-over-year basis. equities analysts forecast that Celgene Co. will post 7.66 EPS for the current year.
Celgene declared that its board has authorized a stock buyback program on Wednesday, February 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.
In other Celgene news, insider Mark J. Alles acquired 3,260 shares of the stock in a transaction on Thursday, February 8th. The shares were purchased at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the acquisition, the insider now owns 178,904 shares in the company, valued at approximately $16,441,277.60. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $94.83, for a total transaction of $877,177.50. Following the transaction, the director now owns 94,801 shares in the company, valued at approximately $8,989,978.83. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,120 shares of company stock worth $3,879,509. Corporate insiders own 0.95% of the company’s stock.
A number of equities research analysts have recently commented on the stock. Vetr lowered shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective on the stock. in a research note on Monday, December 18th. Credit Suisse Group set a $128.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Tuesday, December 12th. Deutsche Bank assumed coverage on shares of Celgene in a research note on Tuesday, December 12th. They issued a “hold” rating and a $114.00 price objective on the stock. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Celgene in a research note on Sunday, December 10th. Finally, Oppenheimer set a $166.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Thursday, December 14th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $128.22.
TRADEMARK VIOLATION WARNING: “Shelton Capital Management Trims Holdings in Celgene Co. (CELG)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://ledgergazette.com/2018/03/17/shelton-capital-management-trims-holdings-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.